Todd Yezefski
YOU?
Author Swipe
View article: 864 Delineating the role of growth differentiation Factor 15 (GDF-15) in advanced bladder and upper tract urinary cancers (BC): university of Washington rapid autopsy program (UW-RAP) cohort
864 Delineating the role of growth differentiation Factor 15 (GDF-15) in advanced bladder and upper tract urinary cancers (BC): university of Washington rapid autopsy program (UW-RAP) cohort Open
View article: PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received<sup>177</sup>Lu-PSMA-617: Importance of<sup>18</sup>F-FDG–Avid Discordant Findings
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received<sup>177</sup>Lu-PSMA-617: Importance of<sup>18</sup>F-FDG–Avid Discordant Findings Open
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with 177Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION a…
View article: SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving<sup>177</sup>Lu-PSMA-617
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving<sup>177</sup>Lu-PSMA-617 Open
177Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study …
View article: Proton radiation therapy for stage IIA/IIB testicular seminoma
Proton radiation therapy for stage IIA/IIB testicular seminoma Open
View article: Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy Open
View article: Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors
Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors Open
Purpose: High-throughput profiling experiments have linked altered expression of microRNAs (miRNA) to different types of cancer. Tumor tissues are a heterogeneous mixture of not only cancer cells, but also supportive and reactive tu…
View article: Supplementary Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors
Supplementary Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors Open
Supplementary Figures S1-S7 and Supplementary Tables S1-S3.
View article: Supplementary Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors
Supplementary Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors Open
Supplementary Figures S1-S7 and Supplementary Tables S1-S3.
View article: Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors
Data from Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors Open
Purpose: High-throughput profiling experiments have linked altered expression of microRNAs (miRNA) to different types of cancer. Tumor tissues are a heterogeneous mixture of not only cancer cells, but also supportive and reactive tu…
View article: Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer Open
PURPOSE Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling…
View article: Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer Open
View article: Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations Open
Background Among men with metastatic prostate cancer, about 10% have germline alterations in DNA damage response genes. Most studies have examined BRCA2 alone or an aggregate of BRCA1/2 and ATM . Emerging data suggest that ATM mutations ma…
View article: Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer Open
Background Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)‐targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. Therefore, we sought to …
View article: Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program Open
View article: Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes
Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes Open
BACKGROUND: Plasmacytoid urothelial carcinoma is a rare bladder cancer variant with scarce data on outcomes and prognostic factors. OBJECTIVE: We report our institutional experience with this histology to determine response to neoadjuvant …